Search

everythinglearnresearchcommunity

for

Search:↓

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

PP405 is a new hair loss treatment facing mixed reactions due to initial hype and insufficient data. Some are hopeful, but many doubt its effectiveness compared to minoxidil and finasteride.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.

PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

PP405 might take 3-4 years to be available, but some claim Everychem offers a similar product, though its effectiveness is debated. Users discuss the risks of using untested grey market products and the potential for adverse effects.

Low-Level Laser Therapy (LLLT) is seen as a safe and effective method for maintaining hair and promoting regrowth in androgenetic alopecia (AGA) and male pattern baldness (MPB), with devices like the HairMax LaserComb® and iRestore helmet being popular. Some users and professionals are skeptical about its long-term effectiveness and cost.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.

A fake hair loss product called "PP405" is being humorously discussed, with users joking about its effectiveness and availability on resale websites. The consensus is that it's a scam, with some users sarcastically claiming miraculous results.

User discusses trying Low Level Laser Therapy (LLLT) for hair loss and its high cost. Another user shares their experience combining micro needling, minoxidil, and LLLT, seeing positive results after 2 months.

PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

People are eagerly awaiting the release of PP405, a new hair loss treatment. Some are using minoxidil and finasteride in the meantime, but there are concerns about scams and unverified products.

PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.

PP405 is being discussed for hair regrowth, with mixed opinions on its effectiveness and legitimacy. Some users report early signs of regrowth, while others are skeptical about its authenticity and results.

PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.

Microneedling combined with latanoprost may convert vellus hairs to transitional or terminal hairs. The user suggests using oral minoxidil to increase vellus hair, then applying a high concentration of latanoprost with microneedling for conversion.